News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Talon Therapeutics, Inc. (TLON.OB) Reports Fourth Quarter and Year End 2012 Financial Results


4/1/2013 10:25:33 AM

SOUTH SAN FRANCISCO, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCQB:TLON), today reported financial results for the fourth quarter and year ended December 31, 2012.

2012 Corporate Highlights

FDA accelerated approval of Marqibo® for the treatment of Philadelphia chromosome negative adult acute lymphoblastic leukemia (ALL) patients in second or greater relapse or whose disease has progressed following two or more prior lines of anti-leukemia therapy.

Enrollment and dosing of the first patient in the Phase 3 confirmatory study of Marqibo®, named HALLMARQ, in adult patients with newly diagnosed Philadelphia chromosome negative ALL.

Publication of the Marqibo® RALLY Study in the Journal of Clinical Oncology (JCO).


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES